Kyntra Bio, Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.5 million (-209.3% year over year) and diluted EPS of $2.96. It usually reports 41–75 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 9, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 10, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–75 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
-1
-209.3%
|
12
+257.5%
|
2.96
+257.4%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
4
+36.5%
|
-15
-427.6%
|
-3.76
-427.0%
|
|
Mar 16, 2026
75 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
-59.3%
|
-14
-179.1%
|
-3.51
-178.9%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
+774.8%
|
201
+1274.4%
|
49.61
+1267.3%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
+35.1%
|
-8
+51.1%
|
-1.88
+51.7%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
-89.2%
|
5
+114.1%
|
1.15
+448.5%
|
|
Feb 20, 2025
51 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3
+104.2%
|
18
+132.0%
|
4.46
+880.6%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
-99.7%
|
-17
+73.1%
|
-4.25
-553.8%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KYNB (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 921299
- Former names
- FIBROGEN INC (until Jan 7, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.